Harshad Kulkarni

Phase 3 Trial of ¹⁷⁷ Lu-Dotatate for Midgut Neuroendocrine Tumors

Jonathan Strosberg, Ghassan El‐Haddad, Edward M. Wolin et al. · New England Journal of Medicine · 2017 · 3.2K citations · Full text

Medicine, Oncology, Pharmacology +17

German Multicenter Study Investigating¹⁷⁷Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients

Kambiz Rahbar, Hojjat Ahmadzadehfar, Clemens Kratochwil et al. · Journal of Nuclear Medicine · 2016 · 832 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

⁶⁸Ga- and ¹⁷⁷Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies

Martina Weineisen, Margret Schottelius, Jakub Šimeček et al. · Journal of Nuclear Medicine · 2015 · 532 citations · Full text

Medicine, Oncology, Pharmacology +17

¹⁷⁷Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy

Richard P. Baum, Harshad Kulkarni, Christiane Schuchardt et al. · Journal of Nuclear Medicine · 2016 · 526 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using ¹⁷⁷Lu-FAP-2286: First-in-Humans Results

Richard P. Baum, Christiane Schuchardt, Aviral Singh et al. · Journal of Nuclear Medicine · 2021 · 327 citations · Full text

Medicine, Nuclear Medicine, Oncology +17